{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:40:41Z","timestamp":1787262041921,"version":"build-2736575974"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Male patients with Anderson\u2013Fabry disease (AFD) often exhibit cardiac involvement, characterized by LV hypertrophy (LVH), associated with severe coronary microvascular dysfunction (CMD). Whether CMD is present in patients without LVH, particularly when female, remains unresolved. The aim of the study was to investigate the presence of CMD by positron emission tomography (PET) in AFD patients of both genders, with and without evidence of LVH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We assessed myocardial blood flow following dipyridamole infusion (Dip-MBF) with 13N-labelled ammonia by PET in 30 AFD patients (age 51 \u00b1 13 years; 18 females) and in 24 healthy controls. LVH was defined as echocardiographic maximal LV wall thickness \u226513 mm. LVH was present in 67% of patients (n = 20; 10 males and 10 females). Dip-MBF was reduced in all patients compared with controls (1.8 \u00b1 0.5 and 3.2 \u00b1 0.5 mL\/min\/g, respectively, P &amp;lt; 0.001). For both genders, flow impairment was most severe in patients with LVH (1.4 \u00b1 0.5 mL\/min\/g in males and 1.9 \u00b1 0.5 mL\/min\/g in females), but was also evident in those without LVH (1.8 \u00b1 0.3 mL\/min\/g in males and 2.1 \u00b1 0.4 mL\/min\/g in females; overall P = 0.064 vs. patients with LVH). Analysis of variance (ANOVA) for the 17 LV segments showed marked regional heterogeneity of MBF in AFD (F = 4.46, P &amp;lt; 0.01), with prevalent hypoperfusion of the apical region. Conversely, controls showed homogeneous LV perfusion (F = 1.25, P = 0.23).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coronary microvascular function is markedly impaired in AFD patients irrespective of LVH and gender. CMD may represent the only sign of cardiac involvement in AFD patients, with potentially important implications for clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hft104","type":"journal-article","created":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T20:26:30Z","timestamp":1372710390000},"page":"1363-1373","source":"Crossref","is-referenced-by-count":66,"title":["Coronary Microvascular Dysfunction is an Early Feature of Cardiac Involvement in Patients with Anderson\u2013Fabry Disease"],"prefix":"10.1093","volume":"15","author":[{"given":"Benedetta","family":"Tomberli","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence \u00a0","place":["Italy"]},{"name":"Referral Center for Myocardial Diseases, Department of Cardiology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence \u00a0","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sciagr\u00e0","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical Physiopathology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical Physiopathology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lisi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Torricelli","sequence":"additional","affiliation":[{"name":"Unit for Genetic Diagnosis, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[{"name":"Metabolic and Muscular Unit, Clinic of Pediatric Neurology, Meyer University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Castelli","sequence":"additional","affiliation":[{"name":"Referral Center for Myocardial Diseases, Department of Cardiology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi H.","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Heart Science Centre, Imperial College London , Harefield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence \u00a0","place":["Italy"]},{"name":"Referral Center for Myocardial Diseases, Department of Cardiology, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,2,7]]},"reference":[{"key":"2026011921162437400_ejhfhft104-bib-0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"2026011921162437400_ejhfhft104-bib-0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet"},{"key":"2026011921162437400_ejhfhft104-bib-0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"2026011921162437400_ejhfhft104-bib-0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"2026011921162437400_ejhfhft104-bib-0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"2026011921162437400_ejhfhft104-bib-0007","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0008","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pcad.2009.11.002","article-title":"Anderson\u2013Fabry disease and the heart","volume":"52","author":"O\u2019Mahony","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0009","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","article-title":"Coronary microvascular dysfunction in male patients with Anderson\u2013Fabry disease and the effect of treatment with alpha galactosidase A","volume":"92","author":"Elliott","year":"2006","journal-title":"Heart"},{"key":"2026011921162437400_ejhfhft104-bib-0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0012","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","article-title":"Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy","volume":"349","author":"Cecchi","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921162437400_ejhfhft104-bib-0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.yjmcc.2011.08.028","article-title":"The coronary circulation and blood flow in left ventricular hypertrophy","volume":"52","author":"Camici","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"2026011921162437400_ejhfhft104-bib-0014","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jacc.2009.04.072","article-title":"The case for myocardial ischemia in hypertrophic cardiomyopathy","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921162437400_ejhfhft104-bib-0015","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","article-title":"Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging","volume":"115","author":"Petersen","year":"2007","journal-title":"Circulation"},{"key":"2026011921162437400_ejhfhft104-bib-0016","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","article-title":"Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene","volume":"81","author":"Ferri","year":"2012","journal-title":"Clin Genet"},{"key":"2026011921162437400_ejhfhft104-bib-0017","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"2026011921162437400_ejhfhft104-bib-0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.echo.2008.11.023","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"22","author":"Nagueh","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"2026011921162437400_ejhfhft104-bib-0019","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2967\/jnumed.107.050138","article-title":"Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy","volume":"49","author":"Sotgia","year":"2008","journal-title":"J Nucl Med"},{"key":"2026011921162437400_ejhfhft104-bib-0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1071-3581(96)90059-8","article-title":"Estimation of myocardial blood flow for longitudinal studies with 13N-labeled ammonia and positron emission tomography","volume":"3","author":"DeGrado","year":"1996","journal-title":"J Nucl Cardiol"},{"key":"2026011921162437400_ejhfhft104-bib-0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"2026011921162437400_ejhfhft104-bib-0022","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/hrt.2005.061911","article-title":"Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance","volume":"92","author":"Perugini","year":"2006","journal-title":"Heart"},{"key":"2026011921162437400_ejhfhft104-bib-0023","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"2026011921162437400_ejhfhft104-bib-0024","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011921162437400_ejhfhft104-bib-0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jacc.2011.05.018","article-title":"Microvascular function is selectively impaired in hypertrophic cardiomyopathy patients with sarcomere myofilament gene mutation","volume":"58","author":"Olivotto","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026011921162437400_ejhfhft104-bib-0026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"2026011921162437400_ejhfhft104-bib-0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0028","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011921162437400_ejhfhft104-bib-0029","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/eurjhf\/hfq211","article-title":"Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A","volume":"13","author":"Machann","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026011921162437400_ejhfhft104-bib-0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"2026011921162437400_ejhfhft104-bib-0031","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2183\/pjab.88.18","article-title":"Pharmacological chaperone therapy for Fabry disease","volume":"88","author":"Ishii","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2026011921162437400_ejhfhft104-bib-0032","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"2026011921162437400_ejhfhft104-bib-0033","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease\u2014current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr Chem Genomics"},{"key":"2026011921162437400_ejhfhft104-bib-0034","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2005.10.050","article-title":"Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy","volume":"47","author":"Olivotto","year":"2006","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft104","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhft104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hft104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hft104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/12\/1363\/66441939\/eurjhf_15_12_1363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/12\/1363\/66441939\/eurjhf_15_12_1363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:20:18Z","timestamp":1768875618000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/12\/1363\/8428815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,1]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,2,7]]},"published-print":{"date-parts":[[2013,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hft104","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,12]]},"published":{"date-parts":[[2013,12,1]]}}}